Label Changes for:
Hyzaar (losartan potassium hydrochlorothiazide) 50-12.5 mg, 100-12.5 mg, and 100-25 mg Tablets
June 2009
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- June 2009
ADVERSE REACTIONS
Losartan Potassium
- General disorders and administration site conditions: Malaise
Hydrochlorothiazide/Post-Marketing Experience
- Hemic: Thrombocytopenia (reworded)
